Patient Stratification
Characterize prognostic subgroups and patient heterogeneity using demographic, clinical, treatment, and—where appropriate—molecular variables.
Solutions
Specialized oncology analytics that complement existing expertise.
GenMabs combines oncology-focused prognostic modeling, risk stratification, value assessment, and analytical consulting to help life-science and healthcare organizations extract additional value from the data, infrastructure, and expertise they already have.
Our Collaboration Principle
Complement. Validate. Create value together.
01
Complement existing teams
Work alongside biostatistics, data science, clinical analytics, RWE, HEOR, informatics, and healthcare economics teams.
02
Build on existing data
Add an oncology-specific analytical layer without requiring organizations to replace established infrastructure.
03
Measure incremental value
Where appropriate, compare the existing approach with the existing approach plus GenMabs oncology analytics.
04
Share analytical ownership
Define endpoints, validation methods, and priorities collaboratively so internal experts remain central to the work.
Three Paths to Value
Different stakeholders. Different questions. One oncology-focused analytical foundation.
01
Pharma & Biopharma
Strengthen oncology evidence generation, patient stratification, translational research, and treatment-outcome analytics.
Explore Pharma & Biopharma → 02Healthcare Providers
Translate patient-level risk into clinical, operational, research, and economic insight.
Explore Healthcare Providers → 03Payers
Connect oncology risk with utilization, cost, care-management prioritization, and value-based oncology.
Explore Payers →Pharma & Biopharma
Oncology analytics for evidence generation and patient stratification.
GenMabs provides an independent oncology-focused analytical layer designed to complement clinical development, biostatistics, biomarker, RWE, HEOR, and data science teams.
Prognostic Modeling
Apply survival analysis, risk scoring, calibration, discrimination, and validation approaches to clinically meaningful oncology questions.
Evidence Generation
Support retrospective studies, external validation, real-world evidence, treatment-context analyses, and outcome characterization.
Clinical & Biomarker Integration
Evaluate opportunities to integrate clinical factors with relevant biomarkers when supported by appropriate partner data and validation.
Sponsor data + internal scientific expertise + GenMabs oncology analytics→deeper patient-level evidence→stronger stratification and validation
Explore a Pharma & Biopharma CollaborationHealthcare Providers
Turn oncology risk into clinical, operational, research, and economic insight.
GenMabs is designed to add oncology-specific prognostic and value-assessment expertise without displacing existing clinical, informatics, biostatistics, quality-improvement, or research teams.
Clinical Value
Evaluate patient- and cohort-level prognostic risk, outcome differences, and clinically meaningful risk groups.
Operational Value
Where institutional data are available, connect risk groups with hospitalization, emergency care, readmission, length of stay, and resource utilization.
Research Value
Support institutional cohort analysis, external validation, outcomes research, survival modeling, and publication-oriented analytical work.
Economic Value
Assess readmission-related cost, episode-of-care economics, resource allocation, avoidable utilization, and value-based care scenarios within the organization's reimbursement environment.
Provider clinical data + institutional expertise + GenMabs oncology analytics→risk insight→clinical, operational, research & economic value
Explore a Healthcare Provider CollaborationPayers
Connect oncology risk with utilization, cost, and value-based care.
Health plans possess extensive claims, utilization, pharmacy, and cost data. GenMabs adds a specialized oncology prognostic layer designed to test whether clinical risk contributes incremental value to existing payer analytics.
ExistingPayer Data & Analytics
+SpecializedGenMabs Oncology Risk Layer
=PotentialEnhanced Risk & Value Assessment
Population Risk
Evaluate oncology-specific risk stratification and identification of high-risk member populations.
Utilization
Assess associations with hospitalization, emergency utilization, readmission, and high-cost oncology episodes.
Care Management
Explore whether validated risk signals can improve prioritization for navigation, symptom monitoring, outreach, and care coordination.
Economic Value
Link clinical risk with 6- or 12-month total cost of care and value-based oncology program evaluation.
The Central Pilot Question
Does oncology-specific prognostic risk add actionable value beyond existing payer analytics?
A narrowly scoped retrospective pilot can compare an existing payer approach with the same approach plus GenMabs oncology risk using discrimination, calibration, high-risk capture, utilization differences, cost differences, and other jointly defined endpoints.
One Foundation. Multiple Paths to Value.
Partner expertise remains central. GenMabs adds specialization. The value is created together.
OncoAI, value assessment, and analytical consulting provide a flexible foundation for collaboration across the oncology ecosystem.